POXEL

POXELPOXEL
P

POXEL

A biopharmaceutical company developing innovative treatments for serious chronic metabolic diseases.

Website
DR 322006ActiveLyon, France
Rate
Advertise here

About

POXEL SA is a clinical-stage biopharmaceutical company focused on developing innovative treatments for serious chronic diseases with a metabolic pathophysiology. Their primary areas of focus include metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic diseases. The company announced a new Tranche D PDR subscription agreement with IPF Partners on March 25, 2026.
Frequently asked

What does POXEL do?

POXEL SA is a clinical-stage biopharmaceutical company focused on developing innovative treatments for serious chronic diseases with a metabolic pathophysiology. Their primary areas of focus include metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic diseases. The company announced a new Tranche D PDR subscription agreement with IPF Partners on March 25, 2026.

What is POXEL's revenue?

StartupHub estimates POXEL's annual revenue at $50.0M (range $33.0M to $113.4M, 43% confidence), based on comparable companies in the sector.

What is POXEL's valuation?

StartupHub estimates POXEL's effective valuation at $987.6M (range $691.3M to $1.3B, 41% confidence), based on comparable companies in the sector.

How much funding has POXEL raised?

POXEL has raised a total of $4M in funding. The most recent round on record is Tranche D PDR Bond Issue.

Where is POXEL headquartered?

POXEL is headquartered in Lyon, France.

When was POXEL founded?

POXEL was founded in 2006.

What industry does POXEL operate in?

POXEL operates in Biotechnology, Pharmaceuticals, Healthcare.

Comments

No comments yet. Be the first to share your take.